TDS Pharm Co (XKRX:464280) Research & Development: ₩633 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:464280 TDS Pharm Co Ltd XKRX:464280
40 GF Score
Price ₩5,520.00
! 1 Warning Sign
View Full Analysis

What is TDS Pharm Co Research & Development?

TDS Pharm Co XKRX:464280 40 Research & Development is ₩633 Mil as of Jun. 2026. GuruFocus rates XKRX:464280 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TDS Pharm Co's Research & Development for the three months ended in Jun. 2026 was ₩157 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ₩633 Mil.

TDS Pharm Co  (XKRX:464280) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TDS Pharm Co Research & Development Related Terms

TDS Pharm Co Research & Development Historical Data

* Premium members only.

The historical data trend for TDS Pharm Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TDS Pharm Co Research & Development Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 356.11 478.84 441.20 622.50 665.91

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.67 156.12 172.37 147.81 157.09
XKRX:464280
40GF Score
TDS Pharm Co Ltd XKRX:464280
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TDS Pharm Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩633 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₩633 Mil mean?
TDS Pharm Co (XKRX:464280) has a Research & Development of ₩633 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on TDS Pharm Co and its competitors.
Is TDS Pharm Co's Research & Development too high?
TDS Pharm Co's current Research & Development is ₩633 Mil. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's Research & Development compare to LLY and JNJ?
TDS Pharm Co's Research & Development of ₩633 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TDS Pharm Co and its competitors. TDS Pharm Co's current Research & Development is ₩633 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current Research & Development of ₩633 Mil. The current Research & Development is ₩633 Mil. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current Research & Development is ₩633 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TDS Pharm Co Business Description

Address 253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score

Get the complete analysis for XKRX:464280

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩5,520.00
Price